Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent(dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in adolescents and adults with skin of colour.
The data were presented at the 2025 Revolutionizing Atopic Dermatitis Conference.
Go deeper with GlobalData
In the study, 120 subjects with AD and skin of colour received Dupixent biweekly.
At the 24-week mark, 76% of them achieved a ≥75% improvement in overall disease severity, with some noticing benefits as early as two weeks.
Additionally, 53% of patients saw a reduction in itch, and there was a 53% decrease in post-inflammatory hyperpigmentation from baseline.
The trial’s safety outcomes aligned with Dupixent’s established safety profile in dermatological uses.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSubjects in the DISCOVER trial, aged 12 years and above, were treated with Dupixent monotherapy based on weight.
The primary endpoint was achieving a minimum of a 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks.
Secondary and additional endpoints are the proportion of subjects achieving ≥4-point improvement on the Peak-Pruritus Numerical Rating Scale (PP-NRS).
The skin of colour was defined as per Fitzpatrick skin types IV-VI.
AD, a chronic skin condition characterised by type 2 inflammation, can be particularly severe in individuals with skin of colour, often leading to more pronounced symptoms and skin lesions.
Invented using Regeneron’s VelocImmune technology, Dupixent is a monoclonal antibody that blocks the signalling of interleukin-4 and interleukin-13 pathways without being an immunosuppressant. It is a collaborative effort between Sanofi and Regeneron.
The companies recently reported that the Phase III AERIFY-1 trial of itepekimab in former smokers who have inadequately controlled chronic obstructive pulmonary disease (COPD), met the primary goal.
